FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

June 27, 2022

Conditions
Immunization
Interventions
OTHER

Fluenz Tetra nasal spray suspension

Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
collaborator

European Commission

OTHER

collaborator

Stanford University

OTHER

lead

University of Oxford

OTHER

NCT04222595 - FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV | Biotech Hunter | Biotech Hunter